irinotecan has been researched along with Leukemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwee, JK; Maia, RC; Marques-Santos, LF; Silva, KL; Vasconcelos, FC | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Meropol, NJ | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Ariyoshi, Y; Ogawa, M | 1 |
| Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
| Eckhardt, SG | 1 |
| Rosen, LS | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
| Arima, T; Ariyoshi, H; Ichimaru, M; Kuramoto, A; Masaoka, T; Oguro, M; Ohno, R; Okada, K; Sakai, Y; Yoshida, Y | 1 |
2 review(s) available for irinotecan and Leukemia
| Article | Year |
|---|---|
[Clinical trials of new antitumor drugs in hematopoietic malignancies].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Doxorubicin; Ethics, Medical; Humans; Idarubicin; Irinotecan; Leukemia; Lymphoma | 1994 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
3 trial(s) available for irinotecan and Leukemia
| Article | Year |
|---|---|
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
6 other study(ies) available for irinotecan and Leukemia
| Article | Year |
|---|---|
CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Cells; Bone Marrow Cells; Camptothecin; Cell Death; Drug Resistance, Multiple; Female; Humans; Interphase; Irinotecan; Leukemia; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phenotype; Rhodamine 123; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2003 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Irinotecan: a review of the initial phase I trials.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Hodgkin Disease; Humans; Irinotecan; Japan; Leukemia; Lymphoma, Non-Hodgkin; United States | 1998 |
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Female; Humans; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged | 1990 |